Volume 117, Issue 4, Pages (October 1999)

Slides:

Advertisements

Similar presentations

Peter R. McNally, DO, FACP, FACG Lone Tree, Colorado

Advertisements

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease Richard N. Fedorak, *, Alfred Gangl, ‡, Charles.

Antibodies to CBir1 Flagellin Define a Unique Response That Is Associated Independently With Complicated Crohn’s Disease Stephan R. Targan, Carol J. Landers,

Volume 137, Issue 4, Pages (October 2009)

Volume 120, Issue 6, Pages (May 2001)

Volume 149, Issue 2, Pages e2 (August 2015)

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Volume 134, Issue 7, Pages (June 2008)

Volume 138, Issue 2, Pages (February 2010)

Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab William J. Sandborn, Maria T. Abreu, Geert.

Abatacept for Crohn's Disease and Ulcerative Colitis

Anti–tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: A case report Philip V. Hassard, Scott W. Binder, Viera.

Volume 135, Issue 4, Pages (October 2008)

Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Anti–Tumor Necrosis Factor-α Agents Christine.

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Volume 133, Issue 1, Pages (July 2007)

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease Stephen B Hanauer, Carrie L Wagner,

Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease William S Mow, Simon K Lo, Stephan.

A Randomized, Double-Masked, Placebo-Controlled Study of Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule 1, for the Treatment of.

Effect of the Prebiotic Oligofructose on Relapse of Clostridium difficile-Associated Diarrhea: A Randomized, Controlled Study Stephen Lewis, Stephen.

Volume 120, Issue 6, Pages (May 2001)

Volume 120, Issue 6, Pages (May 2001)

Risks and Benefits of Infliximab for the Treatment of Crohn’s Disease

Volume 134, Issue 7, Pages (June 2008)

Volume 153, Issue 1, Pages e6 (July 2017)

Oral pentasa in the treatment of active Crohn’s disease: A meta-analysis of double- blind, placebo-controlled trials Stephen B Hanauer, Ulf Strömberg

Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean–Frédéric Colombel, William.

GI clinical research 2002–2003: the year in review

Antje Timmer*, Lloyd R. Sutherland*,‡, Francois Martin§

Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s Disease Elana A. Maser, Renata Villela,

Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection

Volume 130, Issue 2, Pages (February 2006)

Volume 123, Issue 3, Pages (September 2002)

Volume 147, Issue 3, Pages e3 (September 2014)

Severe Constipation Clinical Gastroenterology and Hepatology

A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab Fernando.

Volume 132, Issue 5, Pages (May 2007)

Volume 137, Issue 4, Pages (October 2009)

Volume 119, Issue 6, Pages (December 2000)

Volume 147, Issue 6, Pages e5 (December 2014)

William J. Sandborn, Stefan Schreiber, Brian G

Volume 119, Issue 6, Pages (December 2000)

Volume 145, Issue 5, Pages e5 (November 2013)

Volume 154, Issue 6, Pages (May 2018)

Volume 132, Issue 1, Pages (January 2007)

Brian G. Feagan, Gordon R. Greenberg, Gary Wild, Richard N

Cannabis Induces a Clinical Response in Patients With Crohn's Disease: A Prospective Placebo-Controlled Study Timna Naftali, Lihi Bar-Lev Schleider,

Case Report: Evidence for Transplacental Transfer of Maternally Administered Infliximab to the Newborn Eric A. Vasiliauskas, Joseph A. Church, Neil Silverman,

David H. Bruining, William J. Sandborn

Volume 135, Issue 5, Pages (November 2008)

Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease Gerassimos J.

Volume 121, Issue 5, Pages (November 2001)

Correlation Between the Crohn's Disease Activity and Harvey–Bradshaw Indices in Assessing Crohn's Disease Severity Severine Vermeire, Stefan Schreiber,

Volume 126, Issue 2, Pages (February 2004)

Volume 128, Issue 7, Pages (June 2005)

Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study William J. Sandborn, Stefan Schreiber,

Volume 116, Issue 5, Pages (May 1999)

Volume 142, Issue 5, Pages e2 (May 2012)

Walter Reinisch, Jean-Frederic Colombel, William J

Volume 117, Issue 3, Pages (September 1999)

Michelle Maria Pietzak Gastroenterology

Volume 125, Issue 1, Pages (July 2003)

Gastroenterology Volume 124, Issue 4, (April 2003) DOI: /S (03)

Predicting a Change in Diagnosis From Ulcerative Colitis to Crohn’s Disease: A Nested, Case-Control Study Gil Y. Melmed, Robert Elashoff, Gary C. Chen,

Medical Therapy for Refractory Pediatric Crohn’s Disease

Volume 121, Issue 2, Pages (August 2001)

Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months Gary R. Lichtenstein, Ole Ø. Thomsen,

Volume 157, Issue 4, Pages e6 (October 2019)

Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis Jean-Frédéric Colombel,

(A) Percentage of patients achieving remission or response at week 12 or 24 after initiating ova therapy. (A) Percentage of patients achieving remission.

Presentation transcript:

Volume 117, Issue 4, Pages 761-769 (October 1999) Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease Paul Rutgeerts, Geert D'Haens, Stephan Targan, Eric Vasiliauskas, Stephen B. Hanauer, Daniel H. Present, Lloyd Mayer, Ruud A. Van Hogezand, Tanja Braakman, Kimberly L. DeWoody, Thomas F. Schaible, Sander J.H. Van Deventer Gastroenterology Volume 117, Issue 4, Pages 761-769 (October 1999) DOI: 10.1016/S0016-5085(99)70332-X Copyright © 1999 American Gastroenterological Association Terms and Conditions

Fig. 1 Schematic diagram of the infliximab study design showing both the initial and retreatment phases of the study. HACA, human antichimeric antibodies. Gastroenterology 1999 117, 761-769DOI: (10.1016/S0016-5085(99)70332-X) Copyright © 1999 American Gastroenterological Association Terms and Conditions

Fig. 2 Percentage of patients achieving clinical (A) response or (B) remission in patients undergoing retreatment with placebo (○) or infliximab (●) after an initial treatment with infliximab. Gastroenterology 1999 117, 761-769DOI: (10.1016/S0016-5085(99)70332-X) Copyright © 1999 American Gastroenterological Association Terms and Conditions

Fig. 3 Survival analysis for time to loss of response in patients retreated with placebo (n = 36, dotted line) or infliximab (n = 37, solid line) through 8 weeks after the last infusion of infliximab or placebo. Patients who had a clinical response at any point during the retreatment period were followed up for the duration of response in this analysis. The time axis is the duration of response determined only during the retreatment period. Differences between infliximab retreatment and placebo retreatment for the median time to loss of response had a P value of 0.057. Gastroenterology 1999 117, 761-769DOI: (10.1016/S0016-5085(99)70332-X) Copyright © 1999 American Gastroenterological Association Terms and Conditions

Fig. 4 Median values for (A) CDAI, (B) IBDQ, and (C) CRP concentration in patients retreated with placebo (○) or infliximab (●). Gastroenterology 1999 117, 761-769DOI: (10.1016/S0016-5085(99)70332-X) Copyright © 1999 American Gastroenterological Association Terms and Conditions